Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 6/20 | 0.44 |
| ▸ | KDM4A | O75164 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.44 |
| ▸ | TET3 | O43151 | 2/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873420 | 1.00 | TET2 (0.44) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL16638900 | 0.79 | — | — | |
| SCHEMBL15894683 | 0.79 | — | — | |
| SCHEMBL15485862 | 0.76 | NOS2 (0.47) | — | |
| SCHEMBL28031983 | 0.76 | — | — | |
| SCHEMBL14087200 | 0.76 | NOS2 (0.47) | — | |
| SCHEMBL14164385 | 0.76 | NOS2 (0.47) | — | |
| SCHEMBL28161141 | 0.76 | NOS2 (0.47) | — | |
| SCHEMBL27809324 | 0.76 | GABRR1 (0.46) | — | |
| SCHEMBL30552373 | 0.76 | NOS2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9821001-B2 | Aminoglycosides and uses thereof in the treatment of genetic disorders | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-11-21 | — | — | US | disclosed |
| US-20150352136-A1 | NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352136-A1 | NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | AARS1, NARS1, GOT1 | TET2 3190/4885KDM4A 4115/4885KDM4C 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.